Vaccines & therapeutic clinical trials to boost COVID-19 prevention and treatment (RIA)
As first emergency funding under Horizon Europe the European Commission is mobilising €123 million from Horizon Europe for urgent research into coronavirus variants. With this funding the Commission fuels four new emergency actions. On this page we provide information about the ‘Vaccines & therapeutic clinical trials to boost COVID-19 prevention and treatment (RIA)’ action. For further information download the Infosheet below.
Vaccines & therapeutic clinical trials to boost COVID-19 prevention and treatment (RIA) aims at supporting activities that enable the conduct of vaccine & therapeutic trials to boost prevention and further inform public health policy and clinical management.
Funding rate: 100%
Deadline: 6 May 2021
Duration: No limit; up to 4 years is recommended.
Total budget: €60M
Consortium: At least three legal entities established in different Member States or Associated Countries.
Scope: Proposals submitted under this expression of interest should aim to further develop promising therapeutic or prophylactic candidates against SARS-CoV-2/COVID-19. The vaccine/treatment candidates should have completed preclinical development, including animal studies, and be ready to enter clinical evaluation in Phase I or II studies. Applicants should have addressed the current viral variants of concern in their pre-clinical work, and/or anticipated the emergence of new variants.
Proposals should include a summary of results obtained in the concluded studies (pre-clinical and/or Phase I). Proposals are also expected to include assurances on sufficient and timely access to GMP production of the compound(s) to be trialled (the costs of which can be included in the proposal). In addition, options to upscale production for subsequent development beyond the activities for which funding is requested, should be indicated as appropriate.
(For complete information on the scope of this call, view the infosheet below)
- Enrichment of the current portfolio of SARS-CoV-2 /COVID-19 prophylactics and therapeutics with clinical testing of promising candidates.
- Further development of new, or adjustment of existing, vaccine candidates to be effective against the current SARS-CoV-2 variants and potentially protect against new emerging ones.
- Development of new effective therapies against SARS-CoV-2 for the clinical management of COVID-19 disease, including for the prevention of disease progression to severe illness and hospitalisation.
For complete information on this call, download our Infosheet: HORIZON-HLTH-2021-CORONA-01-01 Vaccines and therapeutic clinical trials
Check out all EC Horizon COVID-19 Emergency Grant Calls
Visit the EC Call webpage